Capital Wealth Planning’s Teva Pharmaceuticals TEVA Stock Holding History

Capital Wealth Planning’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.3M	Buy	806,742 +281,742	+54%	+$9.38M	0.14%	56
2026 Q1	$15.8M	Buy	+525,000	New	+$16.9M	0.09%	75
2025 Q1	–	Sell	-246,601	Closed	-$5.44M	–	161
2024 Q4	$5.44M	Buy	246,601 +20,016	+9%	+$364K	0.05%	38
2024 Q3	$4.08M	Buy	226,585 +65,235	+40%	+$1.14M	0.04%	45
2024 Q2	$2.62M	Buy	161,350 +7,620	+5%	+$117K	0.03%	62
2024 Q1	$2.17M	Buy	+153,730	New	+$1.94M	0.02%	62
2021 Q3	–	Sell	-23,400	Closed	-$232K	–	144
2021 Q2	$232K	Sell	23,400 -5,000	-18%	-$52.9K	0.01%	116
2021 Q1	$328K	Hold	28,400	–	–	0.01%	91
2020 Q4	$356K	Sell	28,400 -4,800	-14%	-$46K	0.01%	77
2020 Q3	$299K	Buy	33,200 +300	+0.9%	+$3.17K	0.01%	81
2020 Q2	$406K	Buy	32,900 +2,313	+8%	+$26.2K	0.02%	78
2020 Q1	$275K	Buy	+30,587	New	+$313K	0.02%	175
2019 Q4	–	Sell	-28,687	Closed	-$234K	–	239
2019 Q3	$234K	Buy	28,687 +6,900	+32%	+$52.9K	0.01%	222
2019 Q2	$201K	Buy	+21,787	New	+$263K	0.01%	235

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Capital Wealth Planning's TEVA Position: Q2 2026 in Review

Capital Wealth Planning increased its Teva Pharmaceuticals (TEVA) stake by 54% in Q2 2026, buying an estimated $9.38M and bringing the position to 806,742 shares worth $27.3M. The position accounts for 0.14% of the portfolio, ranked #56.

Capital Wealth Planning first reported a position in TEVA in Q2 2019 and has held it in 14 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Capital Wealth Planning held 806,742 shares of Teva Pharmaceuticals worth $27.3M as of Q2 2026.
Capital Wealth Planning bought 281,742 Teva Pharmaceuticals shares in Q2 2026, an estimated $9.38M.
Teva Pharmaceuticals made up 0.14% of Capital Wealth Planning's portfolio in Q2 2026, its #56 holding.
Capital Wealth Planning first reported a position in Teva Pharmaceuticals in Q2 2019 and has held it in 14 quarters since.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Capital Wealth Planning's 13F filing for Q2 2026, filed 14 Aug 2026.